Kymab and EpimAb Biotherapeutics Announce Multi-Target, Bispecific Antibody Cross-Licensing Agreement

Kymab Limited (“Kymab”), a leading human mooclonal antibody biopharmaceutical company, and EpimAb Biotherapeutics, Inc (“EpimAb”), an emerging biopharmaceutical company specialising in bispecific antibodies, today announced a cross-licensing and development agreement to develop bispecific therapeutic antibodies against multiple targets. The parties will focus their efforts on immuno-oncology and will combine antibodies sourced from Kymab’s proprietary Kymouse™ platform with EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig™) platform to generate multiple bispecific antibodies. Kymab will have the development and commercialisation rights to these bispecifics in all geographical regions outside of China, and, under the terms of the cross-license agreement, EpimAb will have the rights to the China market. Each party is eligible to receive milestone payments and royalties for development programmes pursued by the other party.